This Poster presentation is under embargo until 1 May 2026, as per congress regulations.

Please subscribe using the button below to receive a notification when the material becomes available:

Register for email alerts

Publication
  • CCR East •
  • 1 May, 2026 •
  • •

Baseline Pharmacodynamic Markers and Response to Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Edward M. Behrens, Sebastian J. Vastert, Jordi Antón, Pierre Quartier, Bruno Fautrel, Paul Brogan, Melissa Elder, Francesca Minoia, Pavla Dolezalova, Robert Biesen, Masaki Shimizu, Uwe Ullman, Adnan Mahmood, Andrew Danquah, Elena Burillo, Steve Mallett, Brian D. Jamieson, Alexei A. Grom, Fabrizio De Benedetti

Publication
  • CCR East •
  • 1 May, 2026 •
  • •

Emapalumab Treatment for Patients with Differing Presentations of Macrophage Activation Syndrome (MAS) Secondary to Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Alexei A. Grom, Sebastian J. Vastert, Jordi Antón, Pierre Quartier, Bruno Fautrel, Paul Brogan, Edward M. Behrens, Melissa Elder, Francesca Minoia, Pavla Dolezalova, Robert Biesen, Masaki Shimizu, Uwe Ullman, Adnan Mahmood, Andrew Danquah, Elena Burillo, Steve Mallett, Brian D. Jamieson, Fabrizio De Benedetti

Publication
  • PRYSM •
  • 19 March, 2026 •
  • •

Efficacy and Safety of Emapalumab in Patients with Macrophage Activation Syndrome (MAS) in Systemic Lupus Erythematosus (SLE)

Alexei A. Grom, Shoghik Akoghlanian, Melissa Elder, Renee Modica, Steve Mallett, Brian Jamieson, Fabrizio De Benedetti

Available materials

Poster
Publication
  • AMCP Nexus •
  • 28 October, 2025 •
  • •

Economic Burden of Macrophage Activation Syndrome (MAS) in Patients With Still’s Disease (Systemic Juvenile Idiopathic Arthritis [sJIA] and Adult-onset Still’s Disease [AOSD]): Analysis of a US National Administrative Claims Database

Michael Marrone, Christopher McPherson, Abiola Oladapo

Available materials

Poster
Publication
  • ACR •
  • 28 October, 2025 •
  • •

Economic Burden of Macrophage Activation Syndrome (MAS) in Patients with Still’s Disease (Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s Disease (AOSD): Analysis of a US National Administrative Claims Database

Michael Marrone, Christopher McPherson, Abiola Oladapo

Available materials

Poster
Publication
  • ACR •
  • 27 October, 2025 •
  • •

Emapalumab Treatment for Patients with Differing Presentations of Macrophage Activation Syndrome (MAS) Secondary to Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Alexei A. Grom, Sebastian J. Vastert, Jordi Antón, Pierre Quartier, Bruno Fautrel, Paul Brogan, Edward M. Behrens, Melissa Elder, Francesca Minoia, Pavla Dolezalova, Robert Biesen, Masaki Shimizu, Uwe Ullmann, Adnan Mahmood, Andrew Danquah, Elena Burillo, Marco Petrimpol, Steve Mallett, Brian D. Jamieson, Fabrizio De Benedetti

Available materials

Oral Presentation
Sign up for alerts